In advanced dry disease, a key problem is failure of retinal pigment epithelium, often shortened to RPE. These cells help ...

Companies across the globe are diligently working toward developing novel Dry Age Macular Degeneration treatment therapies ...

GlobalData is the parent company of Clinical Trials Arena. "Ocugen sets sights on Phase III after GA gene therapy win" was ...

Scientists at USC are launching a new trial to test a tiny stem cell implant that could restore vision in people with ...

Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...

An editorial published today in The New England Journal of Medicine (NEJM) writes that Science Corporation's PRIMA implant is the first treatment in clinical trials to successfully restore functional ...

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...

Ocugen has announced positive preliminary 12-month data from its phase 2 ArMaDa trial evaluating OCU410 (AAV5-RORA) for the ...

Medically reviewed by Christine L. Larsen, MD Key Takeaways Macular degeneration is a common eye disease, affecting more than 19 million people in the United States alone.The condition can reduce a ...

If your vision is blurry or fuzzy, or if you notice that straight lines appear curved or wavy, you may have age-related macular degeneration (AMD). This eye disease is more common in older adults and ...

People with macular degeneration and other forms of central vision loss can see details like text and faces with this device.

Subretinal transplantation of retinal pigment epithelium derived from human embryonic stem cells (hESCs) appears to be a well-tolerated means of treating age-related macular degeneration and Stargardt ...